8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2025 / Randomized controlled trial (2x2 factorial)
In an ancillary study to the COSMOS trial, 21,442 older adults were randomized to receive daily cocoa extract (500 mg/d flavanols, 80 mg/d (-)-epicatechin), a daily multivitamin/multimineral (MVM; Centrum Silver), both, or placebos for a median of 3.6 years. During follow-up, 2,083 incident clinical fractures occurred. Compared with placebo, cocoa extract did not significantly reduce the risk of incident clinical fracture (aHR 1.03, 95% CI 0.95-1.12) or nonvertebral fracture (aHR 1.05, 95% CI 0.96-1.14). Similarly, MVM supplementation was not associated with lower risk of total clinical fracture (aHR 1.09, 95% CI 1.00-1.19), hip fracture (aHR 1.06, 95% CI 0.80-1.42), or nonvertebral fracture (aHR 1.10, 95% CI 1.00-1.20).
Crandall CJ, Chou S, Kim E, et al. J Bone Miner Res, 2025. PMID 39964350
2025 / Double-blind, placebo-controlled, 2x2 factorial randomized trial
As an ancillary study of the COSMOS trial, 21,442 older US adults were randomized to receive a daily cocoa extract supplement (500 mg/day flavanols, including 80 mg (-)-epicatechin) or placebo. Over a median of 3.6 years, 344 participants experienced a confirmed AMD event. There were 159 cases (1.5%) in the cocoa extract group compared to 185 cases (1.7%) in the placebo group, showing no significant overall effect (HR, 0.87; 95% CI, 0.71-1.08; P = .21). Due to nonproportional hazards, separate models suggested a reduced risk during the first 2 years (HR, 0.77; 95% CI, 0.59-1.01) but no benefit beyond 2 years (HR, 1.06; 95% CI, 0.76-1.50).
Christen WG, Rist PM, Moorthy MV, et al. JAMA Ophthalmol, 2025. PMID 40146119
2024 / Multicenter randomized controlled trial
A 1:1 randomized controlled trial evaluated the effects of a 20-week intensive multidomain lifestyle intervention versus a wait-list usual care control group in 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease. After 20 weeks, significant between-group differences favored the intervention group in CGIC (p = 0.001), CDR-SB (p = 0.032), and CDR Global (p = 0.037), with borderline significance for ADAS-Cog (p = 0.053). The intervention group improved on CGIC, CDR Global, and ADAS-Cog and had significantly less progression on CDR-SB, while the control group worsened on all four measures. Plasma Aβ42/40 ratio increased in the intervention group and decreased in controls (p = 0.003), and the microbiome improved only in the intervention group (p < 0.0001).
Ornish D, Madison C, Kivipelto M, et al. Alzheimers Res Ther, 2024. PMID 38849944
2023 / Randomized controlled trial
Postmenopausal women were randomized to a 12-week intervention including a low-fat, vegan diet and cooked soybeans (1/2 cup [86 g] daily) or a control group with no dietary changes. In the intervention group, moderate-to-severe hot flashes decreased by 88% compared to 34% in the control group (between-group P < 0.001). At 12 weeks, 50% of completers in the intervention group reported no moderate-to-severe hot flashes, compared to no change from baseline among controls (P < 0.001). The intervention group also experienced greater reductions in vasomotor (P = 0.004), physical (P = 0.01), and sexual (P = 0.03) domains of quality of life, with improvements independent of equol production status or seasonality.
Barnard ND, Kahleova H, Holtz DN, et al. Menopause, 2023. PMID 36253903
2023 / Randomized, double-blind, placebo-controlled 3-arm comparative trial
A 6-month randomized, double-blind, placebo-controlled study evaluated 48 subjects with moderate Alzheimer's disease dementia assigned to 400 mg twice daily of placebo, unformulated standard curcumin complex, or bioavailable CurQfen-curcumin (CGM). Supplementation with CGM led to significant improvements (P < 0.05) in Mini-Mental State Examination (MMSE) and Geriatric Locomotive Function Scale (GLFS) scores in both intra- and inter-group comparisons. Analysis of serum biomarkers (BDNF, Aβ42, tau protein, IL-6, and TNF-α) also demonstrated significant improvement (P < 0.05) in the CGM group compared to both placebo and unformulated curcumin.
Das SS, Gopal PM, Thomas JV, et al. Front Dement, 2023. PMID 39081970
2022 / Randomized, double-blind, placebo-controlled study
A randomized, double-blind, placebo-controlled study evaluated the effects of 250 mg daily nicotinamide mononucleotide (NMN) taken in the morning (AM) or afternoon (PM) for 12 weeks among 108 older adults across four groups. Five-times sit-to-stand (5-STS) improved post-intervention in all groups, while drowsiness improved at mid- and post-intervention in the NMN_PM and Placebo_PM groups. The NMN_PM group exhibited the largest effect sizes for 5-STS (d = 0.72) and drowsiness (d = 0.64). Overall, afternoon NMN intake effectively improved lower limb function and reduced drowsiness.
Kim M, Seol J, Sato T, et al. Nutrients, 2022. PMID 35215405
2022 / Double-blind randomized phase I clinical trial
A double-blind phase I trial evaluated oral nicotinamide riboside (NR; 1,000 mg daily) versus placebo for 30 days in 30 newly diagnosed, treatment-naive Parkinson's disease patients. NR was well tolerated and caused a significant, though variable, increase in cerebral NAD levels and related CSF metabolites. Patients with increased brain NAD levels showed altered cerebral metabolism that was linked to mild clinical improvement. NR also upregulated processes linked to mitochondrial, lysosomal, and proteasomal function in blood and/or muscle, and lowered inflammatory cytokines in serum and CSF.
Brakedal B, Dölle C, Riemer F, et al. Cell Metab, 2022. PMID 35235774
2022 / Placebo-controlled, randomized, double-blind, parallel-group trial
In a randomized, double-blind trial, 30 healthy volunteers received either 250 mg/day of NMN (n = 15) or a placebo (n = 15) for 12 weeks. Oral NMN caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed. Whole blood NAD+ and nicotinic acid mononucleotide (NAMN) levels were significantly increased after NMN administration, while NMN levels themselves were not. Additionally, the increase in NAD+ was strongly correlated with pulse rate prior to NMN administration.
Okabe K, Yaku K, Uchida Y, et al. Front Nutr, 2022. PMID 35479740
2021 / Randomized, double-blind, placebo-controlled crossover trial
In a 24-month crossover trial, 125 postmenopausal women aged 45-85 years took 75 mg trans-resveratrol or placebo twice daily for 12 months, followed by the alternative treatment for 12 months. Compared to placebo, resveratrol resulted in a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Resveratrol also improved resting mean cerebral blood flow velocity (d = 0.275, P = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, P = 0.027) and cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025), and insulin resistance index (d = 0.102, P = 0.034). Women aged 65 and older showed a relative improvement in verbal memory compared to those younger than 65 years.
Thaung Zaw JJ, Howe PR, Wong RH Clin Nutr, 2021. PMID 32900519
2021 / Randomized, double-blind, crossover trial
Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.
do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012
2021 / Multicenter randomized controlled trial
The OMEMI trial evaluated whether adding 1.8 g of n-3 PUFA (930 mg EPA and 660 mg DHA) daily versus corn oil placebo to standard of care reduced cardiovascular events over 2 years in patients aged 70 to 82 years with recent AMI. Among 1014 analyzed patients, the primary composite endpoint occurred in 21.4% (108/505) of the n-3 PUFA group and 20.0% (102/509) of the placebo group (HR 1.08 [95% CI, 0.82-1.41]; P=0.60). New atrial fibrillation occurred in 7.2% vs 4.0% (HR 1.84 [95% CI, 0.98-3.45]; P=0.06), and major bleeding occurred in 10.7% vs 11.0% (P=0.87). The authors concluded they could not detect a reduction in clinical events with 1.8 g n-3 PUFAs daily for 2 years in this population.
Kalstad AA, Myhre PL, Laake K, et al. Circulation, 2021. PMID 33191772
2021 / Prospective randomised double-blind sham-controlled study
In a prospective randomised double-blind sham-controlled trial, 62 participants with mild cognitive impairment were allocated to whole-body cryotherapy (-110 °C to -160 °C; n = 33) or a placebo control group (n = 29). After the 10th session (T2), significant differences favored the cryotherapy group in immediate recall (DemTect) and orientation (TYM). Improvements in mood were detected in self-reported depressive symptoms (T2 p = 0.04; VAS mood T2 p = 0.02; T3 p = 0.07), alongside a significant reduction in BDNF level (p < 0.05).
Rymaszewska J, Lion KM, Stańczykiewicz B, et al. Exp Gerontol, 2021. PMID 33454354
2021 / Randomized controlled trial
A randomized trial investigated whether daily oral almond consumption increases UVB resistance and reduces skin aging in 39 healthy Asian women (18-45 years, Fitzpatrick skin type II-IV). Participants consumed either 1.5 oz of almonds or 1.8 oz of pretzels daily for 12 weeks. The minimal erythema dose (MED) increased in the almond group compared to the pretzel group. No differences were observed between groups in facial Allergan roughness, melanin, hydration, or sebum.
Li JN, Henning SM, Thames G, et al. J Cosmet Dermatol, 2021. PMID 33491323
2021 / Randomized controlled trial
In a 1-year randomized controlled trial, 208 healthy older adults were assigned to carbohydrate (CARB), collagen (COLL), whey protein (WHEY), light resistance training plus whey (LITW), or heavy resistance training plus whey (HRTW). COLL and WHEY alone did not affect any measured parameter compared to CARB. Compared to WHEY, HRTW increased quadriceps cross-sectional area (+1.68 cm2; 95% CI: +0.41 to +2.95 cm2; P = 0.03), dynamic strength (+18.4 Nm; P < 10-4), and isometric strength (+23.9 Nm; P < 10-5), while LITW improved dynamic knee extensor strength (+13.7 Nm; P = 0.01) without improving muscle size.
NANO counterpoint →
Mertz KH, Reitelseder S, Bechshoeft R, et al. Am J Clin Nutr, 2021. PMID 33564844
2021 / Randomized, double-blind, controlled trial
A randomized, double-blind, controlled trial evaluated the effects of 32 days of NAD+-precursor supplementation (207.5 mg niacin equivalents/day from tryptophan, nicotinic acid, and nicotinamide) versus control in 14 older adults with impaired physical function. Skeletal muscle NAD+ concentrations were not significantly different between intervention and control (7.5 ± 1.9 vs 7.9 ± 1.6 AU), although methyl-nicotinamide levels were significantly higher (0.098 ± 0.063 vs 0.025 ± 0.014; P = 0.001). Neither ADP-stimulated mitochondrial respiration (82.1 ± 19.0 vs 84.0 ± 19.2; P = 0.716), maximally uncoupled mitochondrial respiration (103.4 ± 30.7 vs 108.7 ± 33.4; P = 0.495), nor net exercise efficiency (20.2 ± 2.77 vs 20.8 ± 2.88; P = 0.342) improved with supplementation.
Connell NJ, Grevendonk L, Fealy CE, et al. J Nutr, 2021. PMID 34191033
2021 / Randomized controlled trial
Postmenopausal women were randomly assigned to a low-fat, vegan diet including 1/2 cup (86 g) of cooked soybeans daily, or to no diet changes for 12 weeks. Total hot flashes decreased 79% in the intervention group compared to 49% in controls (between-group P = 0.01), and moderate-to-severe hot flashes decreased 84% versus 42% (between-group P = 0.01). Furthermore, 59% (10/17) of the intervention group became free of moderate and severe hot flashes, while the control group saw no change (between-group P < 0.001). Significantly greater improvements were also observed in the intervention group across vasomotor, psychosocial, physical, and sexual quality of life domains.
Barnard ND, Kahleova H, Holtz DN, et al. Menopause, 2021. PMID 34260478
2021 / 16-week, double-blind, randomized, placebo-controlled trial
A 16-week, double-blind, randomized, placebo-controlled trial investigated whether nutritional supplements enhance adaptations to twice-weekly resistance training in 200 pre-frail and frail elderly individuals. Across four sub-investigations, leucine supplementation was ineffective for improving muscle mass and function, and whey, soy, or creatine (alone or combined) failed to enhance resistance training adaptations. Furthermore, no sex-based differences were observed in response to whey. Resistance exercise alone increased muscle mass and function in all sub-investigations, and no adverse effects were reported.
Roschel H, Hayashi AP, Fernandes AL, et al. Clin Nutr, 2021. PMID 34358827
2021 / Randomized, double-blind, placebo-controlled trial
Thirty patients with moderate to mild Alzheimer's disease were randomized to receive 500 mg trans-resveratrol orally once daily or placebo for 52 weeks. Trans-resveratrol did not lead to statistically significant changes in blood or CSF Aβ40, whereas placebo participants showed significant decreases in CSF (P = 0.024) and plasma Aβ40 (P = 0.036). Compared with placebo, trans-resveratrol resulted in a significant reduction in brain volume at 52 weeks (P = 0.011) and a 46% decrease in CSF matrix metallopeptidase 9 (P = 0.033).
Gu J, Li Z, Chen H, et al. Neurol Ther, 2021. PMID 34402024
2020 / Staggered multiple baseline intervention trial
A 6-week in-home multicomponent program combining exercise with behavioral/psychosocial training was translated into community delivery by Area Agencies on Aging case managers. Among 255 enrolled dyads, 207 completed the intervention and 140 completed a 13-month follow-up. Persons with dementia had significant increases in physical activity from pre- to posttreatment (p < .001, ES = .54) and at 13 months (p < .01, ES = .21), as well as increased quality of life pre- to posttreatment (p < .001, ES = .29). Caregiver depression also improved from pre- to posttreatment (p = .01, ES = -.18).
Teri L, Logsdon RG, McCurry SM, et al. Gerontologist, 2020. PMID 30304477
2020 / Double-blind cross-over trial
Twelve young and twelve old men received acute nicotinamide riboside (NR) or placebo in a double-blind cross-over study. NR supplementation increased NADH (51% young; 59% old) and NADPH (32% young; 38% old) in both groups, but only in older men did it decrease urine F2-isoprostanes by 18% (P < 0.05) and tend to raise glutathione (P = 0.078). In older individuals, NR improved isometric peak torque by 8% (P = 0.048) and the fatigue index by 15% (P = 0.012), while having no effect on VO2max, concentric peak torque, or physiological performance in young men.
Dolopikou CF, Kourtzidis IA, Margaritelis NV, et al. Eur J Nutr, 2020. PMID 30725213
2020 / Single-arm non-randomized trial
Ten healthy men received single oral doses of 100, 250, and 500 mg nicotinamide mononucleotide (NMN), with clinical parameters and NMN metabolite pharmacokinetics monitored for 5 hours after each intervention. The single oral doses caused no significant clinical symptoms or changes in heart rate, blood pressure, oxygen saturation, body temperature, ophthalmic examination, or sleep quality. Laboratory analyses showed increases in serum bilirubin and decreases in serum creatinine, chloride, and blood glucose within normal ranges, independent of dose. Plasma concentrations of N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide increased significantly in a dose-dependent manner.
Irie J, Inagaki E, Fujita M, et al. Endocr J, 2020. PMID 31685720
2020 / 12-month double-blind randomized controlled trial
A 12-month randomized controlled trial evaluated 20 g twice daily whey-enriched protein supplementation versus an isocaloric placebo and a no-supplement control in 218 older people with sarcopenia, with all given instructions on home-based exercise, dietary protein, and vitamin D (20 μg/d). The supplements had no significant effect on physical performance; 12-month changes in short physical performance battery scores were -0.55, -0.05, and 0.03 points across control, isocaloric, and protein groups (P = .17), with similar changes in continuous summary physical performance scores (P = .76). Hand grip strength decreased significantly in all groups, calf muscle index showed no differences between groups, and post-trial follow-up found no differences in all-cause mortality or physical functioning. Mild gastrointestinal adverse effects were reported by 56% in both supplement groups.
Björkman MP, Suominen MH, Kautiainen H, et al. J Am Med Dir Assoc, 2020. PMID 31734121
1988 / Review
This article discusses the possible involvement of environmental aluminum in the etiology of Alzheimer disease and senile dementia of the Alzheimer type. The hypothesis is supported by direct and indirect relationships between certain encephalopathies and the abnormal presence of aluminum(III) in human and animal brain tissues. Proposals for further biochemical, toxicological, and analytical work are illustrated.
Shows an association, not proof of cause and effect.
Zatta P, Giordano R, Corain B, et al. Med Hypotheses, 1988. PMID 3412205
1982 / Narrative review / geographic analysis
This article examines evidence regarding the hypothesis that decades-long consumption of milk and dairy products may contribute to certain senile cataracts. It approaches the topic through the geography and history of dairying and global differences in adult lactose malabsorption. Populations with long histories of consuming lactose-rich milk developed persistence of high lactase activity throughout life (PHLA), allowing greater galactose absorption without a corresponding increase in galactokinase activity. The author suggests this may lead to repeated galactose challenges, accumulation of galactitol in the lens, and an increased likelihood of senile cataracts.
Shows an association, not proof of cause and effect.
Simoons FJ Dig Dis Sci, 1982. PMID 6804198